Faster Access to Unapproved Treatments

Overall, the bill streamlines emergency access to therapies while maintaining oversight, which supports innovation, productivity, and efficient service delivery. Safety guardrails, transparency, and timelines largely offset risks of regulatory circumvention.

• Reduces red tape via a pre‑approved list, clear criteria, decision timelines, and a 24/7 support line.
• Encourages innovation and investment by recognizing diverse evidence sources, including foreign data, and enabling earlier patient access.
• Improves government efficiency and patient safety with standardized reporting, annual public reviews, and ministerial powers to curb misuse.
• Builders recommend adding statutory service standards (e.g., 24–72 hours) for letters of authorization and publishing performance dashboards.
• Builders urge real‑time safety monitoring and interoperability with provincial systems to track outcomes and adverse events without adding paperwork.
• Builders suggest clear triggers requiring manufacturers to seek full approval after sustained special‑access supply, to prevent long-term reliance on exemptions.
• Builders encourage transparency by publishing rationales for additions/removals and ensuring equitable access across provinces and small communities.